Healthcare / Diagnostics & ResearchBSE
$504.40
-17.70 (-3.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.5B · quality 84.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
74/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$80.3B
P/E
49.3x
↑EV/EBITDA
29.3x
↑ROE
27.8%
↑Gross Margin
73.5%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+16.3%
FCF CAGR
+31.0%
FCF margin
23.2%
FCF / Net income
1.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.29B · net income $1.63B · FCF $1.92B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.29B | $8.29B | $6.87B | $5.72B | $5.27B |
| Net Income | $1.63B | $1.63B | $915.1M | $707.6M | $644.9M |
| EBITDA | $2.74B | $2.74B | $2.04B | $1.47B | $1.30B |
| EPS | 10.24 | 10.24 | 5.69 | 4.45 | 4.05 |
| Gross Margin | 73.5% | 73.5% | 72.2% | 70.9% | 69.0% |
| Operating Margin | 24.5% | 24.5% | 19.7% | 16.2% | 16.1% |
| Net Margin | 19.7% | 19.7% | 13.3% | 12.4% | 12.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.05 | 0.08 | 0.04 |
| Current Ratio | 3.39 | 3.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.92B | $1.92B | $1.46B | $1.06B | $856.6M |
| Returns | |||||
| ROE | 27.8% | 27.8% | 16.7% | 13.4% | 12.1% |
| Valuation | |||||
| P/E | 49.31 | 49.31 | 40.69 | 47.91 | 36.75 |
| EV/EBITDA | 29.33 | 29.33 | 18.31 | 23.26 | 18.29 |
| P/B | 13.72 | 13.72 | 6.81 | 6.44 | 4.43 |
| Growth & Yield | |||||
| Revenue Growth | 20.6% | 20.6% | 20.2% | 8.6% | — |
| EPS Growth | 80.0% | 80.0% | 28.0% | 9.9% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
63.5%
EPS terminal req.
$44.76
Spread vs growth
16.5%
5Y implied EPS CAGR
39.5%
EPS terminal req.
$54.16
Spread vs growth
40.4%
10Y implied EPS CAGR
23.9%
EPS terminal req.
$87.22
Spread vs growth
56.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+50.8%
Start / end P/E
59.5x → 49.3x
EPS bridge
5.69 → 10.24
Residual
-13.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.